Literature DB >> 3591940

Animal model of primary hyperparathyroidism.

P Jaeger, W Jones, M Kashgarian, R Baron, T L Clemens, G V Segre, J P Hayslett.   

Abstract

An experimental model of hyperparathyroidism was developed in the rat to simulate primary hyperparathyroidism in humans. In this model thyroparathyroidectomized (TPTX) or parathyroidectomized (PTX) animals were infused for 6 days with an amount of bovine synthetic parathyroid hormone (PTH)-(1-34) fragment to restore plasma calcium levels to normal (0.7 U X h-1) or with PTH at twofold (1.4 U X h-1) or threefold (2.1 U X h-1) this basal level. Animals infused with 2.1 U X h-1 of bovine PTH-(1-34) exhibited hypercalcemia, hypophosphatemia, a reduction in theoretical renal threshold for phosphate and an increase in 1,25-dihydroxyvitamin D plasma levels that were approximately threefold the control value. In addition, these animals demonstrated nephrocalcinosis and changes of bone histology that were typical of the findings in patients with primary hyperparathyroidism. In contrast, in animals infused at 1.4 U X h-1, plasma calcium, phosphate, and theoretical renal threshold for phosphate remained within normal limits, but plasma 1,25-dihydroxyvitamin D was increased above control, suggesting that increased activity of 1 alpha-hydroxylase may be the most sensitive index of increased PTH levels. This animal model permits sustained elevation of PTH plasma levels at basal or pathologically elevated levels and should provide an effective means by which to evaluate the consequences of chronic hyperparathyroidism on epithelial function, bone, and other organ systems.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3591940     DOI: 10.1152/ajpendo.1987.252.6.E790

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Parathyroid hormone-related protein stimulates plasma renin activity via its anorexic effects on sodium chloride intake.

Authors:  Douglas K Atchison; Elizabeth Westrick; David L Szandzik; Kevin L Gordish; William H Beierwaltes
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-05-29       Impact factor: 4.310

Review 2.  Calcium-sensing receptor 20 years later.

Authors:  Tariq I Alfadda; Ahmad M A Saleh; Pascal Houillier; John P Geibel
Journal:  Am J Physiol Cell Physiol       Date:  2014-05-28       Impact factor: 4.249

3.  Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture.

Authors:  B G Hory; M C Roussanne; S Rostand; A Bourdeau; T B Drüeke; J Gogusev
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

4.  PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor.

Authors:  Alexandre Loupy; Suresh Krishna Ramakrishnan; Bharath Wootla; Régine Chambrey; Renaud de la Faille; Soline Bourgeois; Patrick Bruneval; Chantal Mandet; Erik Ilso Christensen; Hélène Faure; Lydie Cheval; Kamel Laghmani; Corinne Collet; Dominique Eladari; Robert H Dodd; Martial Ruat; Pascal Houillier
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

5.  Direct action of the parathyroid hormone-like human hypercalcemic factor on bone.

Authors:  D D Thompson; J G Seedor; J E Fisher; M Rosenblatt; G A Rodan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Experimental determination of "the law of bone remodeling" and effect of rat parathyroid hormone (1-34) infusion on derived parameters.

Authors:  C P Jerome; H P Gubler
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

7.  Glucocorticoids possess calcitonin-like antihypercalcemic properties in rats.

Authors:  P F Hirsch; Y Imai; Y Hosoya; H Ode; S Maeda
Journal:  Endocrine       Date:  1998-02       Impact factor: 3.633

8.  Case Report of a Satin Guinea Pig with Fibrous Osteodystrophy That Resembles Human Pseudohypoparathyroidism.

Authors:  Miguel Gallego
Journal:  Case Rep Vet Med       Date:  2017-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.